Partner Perspectives To De-Risk Commercialization Of Combination Products

Developing an effective drug-device combination product for self-administered biologics is a complex process. It requires critical decisions during delivery system selection. Making the right choices at an early stage can reduce risks throughout your drug development journey. Ultimately, a well-executed strategy will help support integration with manufacturing operations and successful drug delivery.

During this webinar, BD and PCI share insights on topics including:

• Design space evolution and potential trade-offs when selecting device components for combination products
• Approaches to de-risk your drug delivery system
• Factors to consider when selecting a CDMO for secondary device assembly with biologics
• Insights into how your delivery system and key partners can support successful commercialization of your combination product